Endocrine Abstracts

Objectives: Estimate the prevalence of of cardiovascular symptoms, to identify the main changes in echocardiography at Graves disease (GD) and their dynamic during treatment.

Methods: Investigated 86 patients with GD. The functional class (FC) chronic heart failure (CHF) was determined according to the New York Heart Association (NYHA). All patients underwent echocardiography before treatment and after 3 months of euthyroid state.

Results: At baseline 32.6% patients had no symptoms of CHF, I FC had 19.7%, II FC – 34.9% and III FC – 12.8%. Tachycardia was presented in 87.2% patients, shortness of breath – 67.4%, arrithmias – 58.1%, pain in the chest – 26, 7%. Patients without CHF and with 1 FC showed no significant differences in the echocardiological parameters compared with the control. Patients with 2 FC observed a higher left ventricular ejection (LVE) (P≤0.05), left ventricular posterior wall thickness (LVPWT) (P≤0.05) and interventricular septum thickness (IVST) (P≤0.05). Patients with 3 FC characterized by an increase of size of the left (P≤0.05) and right atrials (P≤0.05), end-diastolic dimension of left ventricle (EDD LV) (P≤0.05), EDD of left (r≤0.05) and right atrial (P≤0.05). Clinically 3 months after reaching the euthyroid state at 48.8% were maintained complaints of palpitations, at 20.9%- shortness of breath. In patients with FC 2 maintained high LVE, LWPWT, IVST. Among patients with FC 3 also were signs oh heart cavities diliatation.

Conclusions: Cardiovascular symptoms frequently encountered in GD, and some may be stored on reaching euthyrosis. For patients with CHF FC 2 is characterized by left ventricular hypertrophy and myocardial hyperfunction that persist over time during treatment. At 3 FC showed signs of heart cavities diliatatation combined systolic dysfunction, which are only partially reversible with normalization of thyroid function.